How genetic errors in GPCRs affect their function: Possible therapeutic strategies

Genes and Diseases

Volumn 2, Issue 2, 2015, Pages 108-132

  Stoy, Henriette ^a   Gurevich, Vsevolod V ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation; Agonist; Gene therapy; Genetic disorder; GPCR; Mutation

Indexed keywords

ARGIPRESSIN RECEPTOR; ARGIPRESSIN RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; HORMONE RECEPTOR; MELANOCORTIN 4 RECEPTOR; UNCLASSIFIED DRUG;

CELL SURFACE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 84978033649     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2015.02.005     Document Type: Review

References (212)

1. Mackin K.A., Roy R.A., Theobald D.L. An empirical test of convergent evolution in rhodopsins. Mol Biol Evol 2014, 31:85-95.
2. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003, 63:1256-1272.
3. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999, 18:1723-1729.
4. Manglik A., Kobilka B. The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin. Curr Opin Cell Biol 2014, 27:136-143.
5. Pugh E.N., Lamb T.D. Phototransduction in vertebrate rods and cones: molecular mechanisms of amplification, recovery and light adaptation. Handbook of Biological Physics. Molecular Mechanisms in Visual Transduction 2000, 183-255. Elsevier, Amsterdam. D.G. Stavenga, W.J. DeGrip, E.N. Pugh (Eds.).
6. Dixon R.A., Kobilka B.K., Strader D.J., et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
7. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Archives Pharmacol 2002, 366:381-416.
8. Tao Y.X. Constitutive activity in melanocortin-4 receptor: biased signaling of inverse agonists. Adv Pharmacol 2014, 70:135-154.
9. Srinivasan S., Lubrano-Berthelier C., Govaerts C., et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 2004, 114:1158-1164.
10. Vassart G., Pardo L., Costagliola S. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 2004, 29:119-126.
11. Parnot C., Miserey-Lenkei S., Bardin S., Corvol P., Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 2002, 13:336-343.
12. Lebon G., Warne T., Tate C.G. Agonist-bound structures of G protein-coupled receptors. Curr Opin Struct Biol 2012, 22:482-490.
13. Parma J., Duprez L., Van Sande J., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
14. Laue L., Chan W.Y., Hsueh A.J., et al. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A 1995, 92:1906-1910.
15. Gromoll J., Simoni M., Nordhoff V., Behre H.M., De Geyter C., Nieschlag E. Functional and clinical consequences of mutations in the FSH receptor. Mol Cell Endocrinol 1996, 125:177-182.
16. Tao Y.X., Segaloff D.L. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metabolism 2005, 90:5632-5638.
17. Govaerts C., Lefort A., Costagliola S., et al. A conserved Asn in transmembrane helix 7 is an on/off switch in the activation ofthe thyrotropin receptor. J Biological Chem 2001, 276:22991-22999.
18. Parma J., Duprez L., Van Sande J., et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metabolism 1997, 82:2695-2701.
19. Tao Y.X. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 2008, 120:129-148.
20. Venkatakrishnan A.J., Deupi X., Lebon G., Tate C.G., Schertler G.F., Babu M.M. Molecular signatures of G-protein-coupled receptors. Nature 2013, 494:185-194.
21. Smits G., Campillo M., Govaerts C., et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J 2003, 22:2692-2703.
22. Rasmussen S.G., Choi H.J., Fung J.J., et al. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 2011, 469:175-180.
23. Rasmussen S.G., DeVree B.T., Zou Y., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
24. Kang Y., Zhou X.E., Gao X., et al. Crystal structure of rhodopsin bound to arrestin determined by femtosecond X-ray laser. Nature 2014, [revised and resubmitted].
25. Tao Y.X. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol Ther 2006, 111:949-973.
26. Ward N.A., Hirst S., Williams J., Findlay J.B. Pharmacological chaperones increase the cell-surface expression of intracellularly retained mutants of the melanocortin 4 receptor with unique rescuing efficacy profiles. Biochem Soc Trans 2012, 40:717-720.
27. Bichet D.G. V2R mutations and nephrogenic diabetes insipidus. Prog Mol Biol Transl Sci 2009, 89:15-29.
28. Ulloa-Aguirre A., Dias J.A., Bousfield G., Huhtaniemi I., Reiter E. Trafficking of the follitropin receptor. Meth Enzymol 2013, 521:17-45.
29. Heng B.C., Aubel D., Fussenegger M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol Adv 2013, 31:1676-1694.
30. Corvilain B., Van Sande J., Dumont J.E., Vassart G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin Endocrinol 2001, 55:143-158.
31. Kleinau G., Neumann S., Gruters A., Krude H., Biebermann H. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 2013, 34:691-724.
32. Hebrant A., van Staveren W.C., Maenhaut C., Dumont J.E., Leclere J. Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur J Endocrinol/Eur Fed Endocr Soc 2011, 164:1-9.
33. Hamburger J.I. The autonomously functioning thyroid nodule: Goetsch's disease. Endocr Rev 1987, 8:439-447.
34. Sunthornthepvarakui T., Gottschalk M.E., Hayashi Y., Refetoff S. Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 1995, 332:155-160.
35. Chan W.Y. Molecular genetic, biochemical, and clinical implications of gonadotropin receptor mutations. Mol Genet Metab 1998, 63:75-84.
36. Liu G., Duranteau L., Carel J.C., Monroe J., Doyle D.A., Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 1999, 341:1731-1736.
37. Stavrou S.S., Zhu Y.S., Cai L.Q., et al. A novel mutation of the human luteinizing hormone receptor in 46XY and 46XX sisters. J Clin Endocrinol Metabolism 1998, 83:2091-2098.
38. Dierich A., Sairam M.R., Monaco L., et al. Impairing follicle-stimulating hormone (FSH) signaling invivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci U S A 1998, 95:13612-13617.
39. Aittomaki K., Lucena J.L., Pakarinen P., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82:959-968.
40. Tao Y.X., Segaloff D.L. Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci 2009, 89:115-131.
41. Desai S.S., Roy B.S., Mahale S.D. Mutations and polymorphisms in FSH receptor: functional implications in human reproduction. Reproduction 2013, 146:R235-R248.
42. Santini F., Maffei M., Pelosini C., Salvetti G., Scartabelli G., Pinchera A. Melanocortin-4 receptor mutations in obesity. Adv Clin Chem 2009, 48:95-109.
43. Soos S., Petervari E., Szekely M., Jech-Mihalffy A., Balasko M. Complex catabolic effects of central alpha-MSH infusion in rats of altered nutritional states: differences from leptin. JMol Neurosci 2011, 43:209-216.
44. Xu Y., Elmquist J.K., Fukuda M. Central nervous control of energy and glucose balance: focus on the central melanocortin system. Ann N Y Acad Sci 2011, 1243:1-14.
45. Hinney A., Hohmann S., Geller F., et al. Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metabolism 2003, 88:4258-4267.
46. Vaisse C., Clement K., Durand E., Hercberg S., Guy-Grand B., Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000, 106:253-262.
47. Hinney A., Bettecken T., Tarnow P., et al. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metabolism 2006, 91:1761-1769.
48. Lubrano-Berthelier C., Dubern B., Lacorte J.M., et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metabolism 2006, 91:1811-1818.
49. Farooqi I.S., Keogh J.M., Yeo G.S., Lank E.J., Cheetham T., O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003, 348:1085-1095.
50. Tao Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010, 31:506-543.
51. Juul K.V., Bichet D.G., Nielsen S., Norgaard J.P. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiology Ren Physiology 2014, 306:F931-F940.
52. Feldman B.J., Rosenthal S.M., Vargas G.A., et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005, 352:1884-1890.
53. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three- dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995, 25:366-428.
54. Liu W., Chun E., Thompson A.A., et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012, 337:232-236.
55. Katritch V., Cherezov V., Stevens R.C. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 2013, 53:531-556.
56. Vogel R., Mahalingam M., Ludeke S., Huber T., Siebert F., Sakmar T.P. Functional role of the "ionic lock"-an interhelical hydrogen-bond network in family A heptahelical receptors. J Mol Biol 2008, 380:648-655.
57. Yuan S., Filipek S., Palczewski K., Vogel H. Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway. Nat Commun 2014, 5:4733.
58. Dill K.A. Dominant forces in protein folding. Biochemistry 1990, 29:7133-7155.
59. de Roux N., Polak M., Couet J., et al. A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metabolism 1996, 81:2023-2026.
60. Yano K., Kohn L.D., Saji M., Kataoka N., Okuno A., Cutler G.B. A case of male-limited precocious puberty caused by a point mutation in the second transmembrane domain of the luteinizing hormone choriogonadotropin receptor gene. Biochem Biophys Res Commun 1996, 220:1036-1042.
61. Wonerow P., Chey S., Fuhrer D., Holzapfel H.P., Paschke R. Functional characterization of five constitutively activating thyrotrophin receptor mutations. Clin Endocrinol 2000, 53:461-468.
62. Castro I., Lima L., Seoane R., Lado-Abeal J. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas. Thyroid 2009, 19:645-649.
63. Kosugi S., Hai N., Okamoto H., Sugawa H., Mori T. A novel activating mutation in the thyrotropin receptor gene in an autonomously functioning thyroid nodule developed by a Japanese patient. Eur J Endocrinol 2000, 143:471-477.
64. Latronico A.C., Abell A.N., Arnhold I.J., et al. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metabolism 1998, 83:2435-2440.
65. Sheikh S.P., Vilardarga J.P., Baranski T.J., et al. Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J Biological Chem 1999, 274:17033-17041.
66. Varrault A., Le Nguyen D., McClue S., Harris B., Jouin P., Bockaert J. 5-Hydroxytryptamine1A receptor synthetic peptides. Mechanisms of adenylyl cyclase inhibition. J Biological Chem 1994, 269:16720-16725.
67. Ulloa-Aguirre A., Uribe A., Zarinan T., Bustos-Jaimes I., Perez-Solis M.A., Dias J.A. Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression. Mol Cell Endocrinol 2007, 260-262:153-162.
68. Moro O., Lameh J., Hogger P., Sadee W. Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. J Biological Chem 1993, 268:22273-22276.
69. McClue S.J., Baron B.M., Harris B.A. Activation of Gi protein by peptide structures of the muscarinic M2 receptor second intracellular loop. Eur J Pharmacol 1994, 267:185-193.
70. Hu J., Wang Y., Zhang X., et al. Structural basis of G protein-coupled receptor-G protein interactions. Nat Chem Biol 2010, 6:541-548.
71. Moreira I.S. Structural features of the G-protein/GPCR interactions. Biochim Biophys Acta 2014, 1840:16-33.
72. Scheerer P., Park J.H., Hildebrand P.W., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455:497-502.
73. Rosenthal W., Antaramian A., Gilbert S., Birnbaumer M. Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biological Chem 1993, 268:13030-13033.
74. Min L., Ascoli M. Effect of activating and inactivating mutations on the phosphorylation and trafficking of the human lutropin/choriogonadotropin receptor. Mol Endocrinol 2000, 14:1797-1810.
75. Ala Y., Morin D., Mouillac B., et al. Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol 1998, 9:1861-1872.
76. Kremer H., Kraaij R., Toledo S.P., et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 1995, 9:160-164.
77. Jiang X., Liu H., Chen X., et al. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc Natl Acad Sci U. S. A 2012, 109:12491-12496.
78. Jiang X., Dias J.A., He X. Structural biology of glycoprotein hormones and their receptors: insights to signaling. Mol Cell Endocrinol 2014, 382:424-451.
79. Costagliola S., Panneels V., Bonomi M., et al. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J 2002, 21:504-513.
80. Agrawal G., Dighe R.R. Critical involvement of the hinge region of the follicle-stimulating hormone receptor in the activation of the receptor. J Biol Chem 2009, 284:2636-2647.
81. Majumdar R., Dighe R.R. The hinge region of human thyroid-stimulating hormone (TSH) receptor operates as a tunable switch between hormone binding and receptor activation. PloS One 2012, 7:e40291.
82. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biological Chem 1993, 268:4625-4636.
83. Rodien P., Bremont C., Sanson M.L., et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 1998, 339:1823-1826.
84. Dong C., Filipeanu C.M., Duvernay M.T., Wu G. Regulation of G protein-coupled receptor export trafficking. Biochim Biophys Acta 2007, 1768:853-870.
85. Schoneberg T., Schulz A., Biebermann H., Hermsdorf T., Rompler H., Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 2004, 104:173-206.
86. Conn P.M., Ulloa-Aguirre A., Ito J., Janovick J.A. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue invivo. Pharmacol Rev 2007, 59:225-250.
87. Dunham J.H., Hall R.A. Enhancement of the surface expression of G protein-coupled receptors. Trends Biotechnol 2009, 27:541-545.
88. Cohen F.E., Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
89. Conn P.M., Ulloa-Aguirre A. Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab 2010, 21:190-197.
90. Leidenheimer N.J., Ryder K.G. Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharm Res 2014, 83:10-19.
91. Maya-Nunez G., Ulloa-Aguirre A., Janovick J.A., Conn P.M. Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target. Sub-cellular Biochem 2012, 63:263-289.
92. Muntau A.C., Leandro J., Staudigl M., Mayer F., Gersting S.W. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 2014, 37:505-523.
93. Conn P.M., Janovick J.A. Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 2009, 299:137-145.
94. Rene P., Le Gouill C., Pogozheva I.D., et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther 2010, 335:520-532.
95. Fan Z.C., Tao Y.X. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med 2009, 13:3268-3282.
96. Tao Y.X., Huang H. Ipsen 5i is a novel potent pharmacoperone for intracellularly retained Melanocortin-4 receptor mutants. Front Endocrinol 2014, 5:131.
97. Wang X.H., Wang H.M., Zhao B.L., Yu P., Fan Z.C. Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17. J Mol Endocrinol 2014, 53:17-29.
98. Serradeil-Le Gal C., Lacour C., Valette G., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996, 98:2729-2738.
99. Serradeil-Le Gal C. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev 2001, 19:201-214.
100. Ranadive S.A., Ersoy B., Favre H., et al. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol 2009, 71:388-393.
101. Morello J.P., Salahpour A., Laperriere A., et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000, 105:887-895.
102. Wuller S., Wiesner B., Loffler A., et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biological Chem 2004, 279:47254-47263.
103. Bernier V., Morello J.P., Zarruk A., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006, 17:232-243.
104. Bond R.A., Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006, 27:92-96.
105. Huang W., Englund E., Titus S., et al. Identification of thyroid stimulating hormone receptor inverse agonists. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) 2011 Mar 31, [updated 2013 Feb 28].
106. Smit M.J., Leurs R., Alewijnse A.E., et al. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci U. S. A 1996, 93:6802-6807.
107. MacEwan D.J., Milligan G. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 1996, 50:1479-1486.
108. Lee T.W., Cotecchia S., Milligan G. Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists. Biochem J 1997, 325:733-739.
109. Carman C.V., Benovic J.L. G-protein-coupled receptors: turn-ons and turn-offs. Curr Opin Neurobiol 1998, 8:335-344.
110. Gurevich E.V., Tesmer J.J., Mushegian A., Gurevich V.V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 2012, 133:40-69.
111. Gurevich V.V., Gurevich E.V. The structural basis of arrestin-mediated regulation of G protein-coupled receptors. Pharmacol Ther 2006, 110:465-502.
112. Gurevich E.V., Gurevich V.V. Arrestins are ubiquitous regulators of cellular signaling pathways. Genome Biol 2006, 7:236.
113. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. Beta-arrestins and cell signaling. Annu Rev Physiol 2007, 69:483-510.
114. Kim R.Y., al-Maghtheh M., Fitzke F.W., et al. Dominant retinitis pigmentosa associated with two rhodopsin gene mutations. Leu-40-Arg and an insertion disrupting the 5'-splice junction of exon 5. Arch Ophthalmol 1993, 111:1518-1524.
115. Restagno G., Maghtheh M., Bhattacharya S., et al. A large deletion at the 3' end of the rhodopsin gene in an Italian family with a diffuse form of autosomal dominant retinitis pigmentosa. Hum Mol Genet 1993, 2:207-208.
116. Chen J., Makino C.L., Peachey N.S., Baylor D.A., Simon M.I. Mechanisms of rhodopsin inactivation invivo as revealed by a COOH-terminal truncation mutant. Science 1995, 267:374-377.
117. Gurevich V.V., Gurevich E.V. The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 2004, 25:105-111.
118. Gurevich V.V. The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple nonredundant mechanisms. J Biological Chem 1998, 273:15501-15506.
119. Gurevich V.V., Benovic J.L. Visual arrestin binding to rhodopsin: diverse functional roles of positively charged residues within the phosphorylation-recignition region of arrestin. J Biol Chem 1995, 270:6010-6016.
120. Gurevich V.V., Benovic J.L. Mechanism of phosphorylation-recognition by visual arrestin and the transition of arrestin into a high affinity binding state. Mol Pharmacol 1997, 51:161-169.
121. Vishnivetskiy S.A., Paz C.L., Schubert C., Hirsch J.A., Sigler P.B., Gurevich V.V. How does arrestin respond to the phosphorylated state of rhodopsin?. J Biol Chem 1999, 274:11451-11454.
122. Celver J., Vishnivetskiy S.A., Chavkin C., Gurevich V.V. Conservation of the phosphate-sensitive elements in the arrestin family of proteins. J Biological Chem 2002, 277:9043-9048.
123. Kovoor A., Celver J., Abdryashitov R.I., Chavkin C., Gurevich V.V. Targeted construction of phosphorylation-independent b-arrestin mutants with constitutive activity in cells. J Biological Chem 1999, 274:6831-6834.
124. Hirsch J.A., Schubert C., Gurevich V.V., Sigler P.B. The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation. Cell 1999, 97:257-269.
125. Han M., Gurevich V.V., Vishnivetskiy S.A., Sigler P.B., Schubert C. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane translocation. Structure 2001, 9:869-880.
126. Sutton R.B., Vishnivetskiy S.A., Robert J., et al. Crystal structure of cone arrestin at 2.3Å: evolution of receptor specificity. J Mol Biol 2005, 354:1069-1080.
127. Zhan X., Gimenez L.E., Gurevich V.V., Spiller B.W. Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual arrestins. J Mol Biol 2011, 406:467-478.
128. Gray-Keller M.P., Detwiler P.B., Benovic J.L., Gurevich V.V. Arrestin with a single amino acid sustitution quenches light-activated rhodopsin in a phosphorylation-independent fashion. Biochemistry 1997, 36:7058-7063.
129. Song X., Vishnivetskiy S.A., Gross O.P., et al. Enhanced arrestin facilitates recovery and protects rod photoreceptors deficient in rhodopsin phosphorylation. Curr Biol 2009, 19:700-705.
130. Vishnivetskiy S.A., Chen Q., Palazzo M.C., et al. Engineering visual arrestin-1 with special functional characteristics. J Biological Chem 2013, 288:11741-11750.
131. Pan L., Gurevich E.V., Gurevich V.V. The nature of the arrestin x receptor complex determines the ultimate fate of the internalized receptor. J Biological Chem 2003, 278:11623-11632.
132. Barak L.S., Ferguson S.S., Zhang J., Caron M.G. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biological Chem 1997, 272:27497-27500.
133. Gurevich V.V., Dion S.B., Onorato J.J., et al. Arrestin interaction with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, b2-adrenergic, and m2 muscarinic cholinergic receptors. J Biological Chem 1995, 270:720-731.
134. Vishnivetskiy S.A., Hosey M.M., Benovic J.L., Gurevich V.V. Mapping the arrestin-receptor interface: structural elements responsible for receptor specificity of arrestin proteins. J Biol Chem 2004, 279:1262-1268.
135. Vishnivetskiy S.A., Gimenez L.E., Francis D.J., et al. Few residues within an extensive binding interface drive receptor interaction and determine the specificity of arrestin proteins. J Biological Chem 2011, 286:24288-24299.
136. Gimenez L.E., Vishnivetskiy S.A., Baameur F., Gurevich V.V. Manipulation of very few receptor discriminator residues greatly enhances receptor specificity of non-visual arrestins. J Biological Chem 2012, 287:29495-29505.
137. Gimenez L.E., Babilon S., Wanka L., Beck-Sickinger A.G., Gurevich V.V. Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes. Cell Signal 2014, 26:1523-1531.
138. Gurevich V.V., Gurevich E.V. Synthetic biology with surgical precision: targeted reengineering of signaling proteins. Cell Signal 2012, 24:1899-1908.
139. Kim H., Kim J.S. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014, 15:321-334.
140. Gurevich E.V., Gurevich V.V. Beyond traditional pharmacology: new tools and approaches. Br J Pharmacol 2015 Jan 9, in press. 10.1111/bph.13066.
141. Bainbridge J.W., Smith A.J., Barker S.S., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.
142. Cideciyan A.V. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 2010, 29:398-427.
143. Hauswirth W.W., Aleman T.S., Kaushal S., et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-990.
144. Maguire A.M., Simonelli F., Pierce E.A., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-2248.
145. Ahmed M.R., Berthet A., Bychkov E., et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2010, 2. 28ra28.
146. Breitman M., Kook S., Gimenez L.E., et al. Silent scaffolds: inhibition of c-Jun N-terminal kinase 3 activity in the cell by a dominant-negative arrestin-3 mutant. J Biological Chem 2012, 287:19653-19664.
147. Zhan X., Perez A., Gimenez L.E., Vishnivetskiy S.A., Gurevich V.V. Arrestin-3 binds the MAP kinase JNK3α2 via multiple sites on both domains. Cell Signal 2014, 26:766-776.
148. Qi L.S., Larson M.H., Gilbert L.A., et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-1183.
149. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014, 32:343-355.
150. Maeder M.L., Linder S.J., Cascio V.M., Fu Y., Ho Q.H., Joung J.K. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013, 10:977-979.
151. Perez-Pinera P., Ousterout D.G., Brunger J.M., et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods 2013, 10:239-242.
152. Biebermann H., Schoneberg T., Hess C., Germak J., Gudermann T., Gruters A. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 2001, 86:4429-4433.
153. Tan K., Pogozheva I.D., Yeo G.S., et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 2009, 150:114-125.
154. Duprez L., Hermans J., Van Sande J., Dumont J.E., Vassart G., Parma J. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene. J Clin Endocrinol Metabolism 1997, 82:306-308.
155. Evans B.A., Bowen D.J., Smith P.J., Clayton P.E., Gregory J.W. A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype. J Med Genet 1996, 33:143-147.
156. Kraaij R., Post M., Kremer H., et al. A missense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty. JClin Endocrinol Metabolism 1995, 80:3168-3172.
157. Nishihara E., Fukata S., Hishinuma A., et al. Sporadic congenital hyperthyroidism due to a germline mutation in the thyrotropin receptor gene (Leu 512 Gln) in a Japanese patient. Endocrinol Jpn 2006, 53:735-740.
158. Alberti L., Proverbio M.C., Costagliola S., et al. A novel germline mutation in the TSH receptor gene causes non-autoimmune autosomal dominant hyperthyroidism. Eur J Endocrinol 2001, 145:249-254.
159. Esapa C.T., Duprez L., Ludgate M., et al. A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis. Thyroid 1999, 9:1005-1010.
160. Van Sande J., Parma J., Tonacchera M., Swillens S., Dumont J., Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metabolism 1995, 80:2577-2585.
161. Russo D., Arturi F., Suarez H.G., et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metabolism 1996, 81:1548-1551.
162. Dieterich M., Bolz M., Reimer T., Costagliola S., Gerber B. Two different entities of spontaneous ovarian hyperstimulation in a woman with FSH receptor mutation. Reprod Biomed Online 2010, 20:751-758.
163. Smits G., Olatunbosun O., Delbaere A., Pierson R., Vassart G., Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003, 349:760-766.
164. Montanelli L., Van Durme J.J., Smits G., et al. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol Endocrinol 2004, 18:2061-2073.
165. Aycan Z., Agladioglu S.Y., Ceylaner S., Cetinkaya S., Bas V.N., Kendirici H.N. Sporadic nonautoimmune neonatal hyperthyroidism due to A623V germline mutation in the thyrotropin receptor gene. J Clin Res Pediatr Endocrinol 2010, 2:168-172.
166. Paschke R., Tonacchera M., Van Sande J., Parma J., Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metabolism 1994, 79:1785-1789.
167. Latronico A.C., Anasti J., Arnhold I.J., et al. A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metabolism 1995, 80:2490-2494.
168. Ringkananont U., Van Durme J., Montanelli L., et al. Repulsive separation of the cytoplasmic ends of transmembrane helices 3 and 6 is linked to receptor activation in a novel thyrotropin receptor mutant (M626I). Mol Endocrinol 2006, 20:893-903.
169. Kosugi S., Van Dop C., Geffner M.E., et al. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 1995, 4:183-188.
170. Gozu H.I., Bircan R., Krohn K., et al. Similar prevalence of somatic TSH receptor and Gs alpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol 2006, 155:535-545.
171. Yano K., Saji M., Hidaka A., et al. A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J Clin Endocrinol Metabolism 1995, 80:1162-1168.
172. Nijenhuis W.A., Garner K.M., van Rozen R.J., Adan R.A. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 2003, 278:22939-22945.
173. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 2005, 239:1-14.
174. Gozu H., Avsar M., Bircan R., et al. Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules. Thyroid: Official J Am Thyroid Assoc 2005, 15:389-397.
175. Tonacchera M., Chiovato L., Pinchera A., et al. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 1998, 83:492-498.
176. Laue L., Wu S.M., Kudo M., et al. Heterogeneity of activating mutations of the human luteinizing hormone receptor in male-limited precocious puberty. Biochem Mol Med 1996, 58:192-198.
177. Kopp P., Muirhead S., Jourdain N., Gu W.X., Jameson J.L., Rodd C. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor. J Clin Invest 1997, 100:1634-1639.
178. Kosugi S., Shenker A., Mori T. Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptor. FEBS Lett 1994, 356:291-294.
179. Porcellini A., Ciullo I., Laviola L., Amabile G., Fenzi G., Avvedimento V.E. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metabolism 1994, 79:657-661.
180. Wu S.M., Leschek E.W., Brain C., Chan W.Y. A novel luteinizing hormone receptor mutation in a patient with familial male-limited precocious puberty: effect of the size of a critical amino acid on receptor activity. Mol Genet Metab 1999, 66:68-73.
181. Fuhrer D., Tannapfel A., Sabri O., Lamesch P., Paschke R. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocrine-related Cancer 2003, 10:591-600.
182. Shenker A., Laue L., Kosugi S., Merendino J.J., Minegishi T., Cutler G.B. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993, 365:652-654.
183. Yano K., Hidaka A., Saji M., et al. A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/choriogonadotropin receptor gene as familial cases. J Clin Endocrinol Metabolism 1994, 79:1818-1823.
184. Lubrano-Berthelier C., Durand E., Dubern B., et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 2003, 12:145-153.
185. MacKenzie R.G. Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides 2006, 27:395-403.
186. Larsen L.H., Echwald S.M., Sorensen T.I., Andersen T., Wulff B.S., Pedersen O. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metabolism 2005, 90:219-224.
187. Tarnow P., Schoneberg T., Krude H., Gruters A., Biebermann H. Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biological Chem 2003, 278:48666-48673.
188. Beau I., Touraine P., Meduri G., et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest 1998, 102:1352-1359.
189. Martens J.W., Verhoef-Post M., Abelin N., et al. A homozygous mutation in the luteinizing hormone receptor causes partial leydig cell hypoplasia: correlation between receptor activity and phenotype. Mol Endocrinol 1998, 12:775-784.
190. Biebermann H., Krude H., Elsner A., Chubanov V., Gudermann T., Gruters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003, 52:2984-2988.
191. Birnbaumer M. Vasopressin receptor mutations and nephrogenic diabetes insipidus. Arch Med Res 1999, 30:465-474.
192. Pasel K., Schulz A., Timmermann K., et al. Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families. J Clin Endocrinol Metabolism 2000, 85:1703-1710.
193. Rocha J.L., Friedman E., Boson W., et al. Molecular analyses of the vasopressin type 2 receptor and aquaporin-2 genes in Brazilian kindreds with nephrogenic diabetes insipidus. Hum Mutat 1999, 14:233-239.
194. Gu W., Tu Z., Kleyn P.W., et al. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 1999, 48:635-639.
195. Yeo G.S., Lank E.J., Farooqi I.S., Keogh J., Challis B.G., O'Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 2003, 12:561-574.
196. Tonacchera M., Van Sande J., Cetani F., et al. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metabolism 1996, 81:547-554.
197. Oksche A., Schulein R., Rutz C., et al. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function. Mol Pharmacol 1996, 50:820-828.
198. Latronico A.C., Shinozaki H., Guerra G., et al. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J Clin Endocrinol Metabolism 2000, 85:4799-4805.
199. Doherty E., Pakarinen P., Tiitinen A., et al. A novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metabolism 2002, 87:1151-1155.
200. Fuhrer D., Warner J., Sequeira M., Paschke R., Gregory J., Ludgate M. Novel TSHR germline mutation (Met463Val) masquerading as Graves' disease in a large Welsh kindred with hyperthyroidism. Thyroid 2000, 10:1035-1041.
201. Tao Y.X., Segaloff D.L. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 2003, 144:4544-4551.
202. Duprez L., Parma J., Van Sande J., et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994, 7:396-401.
203. Karges B., Krause G., Homoki J., Debatin K.M., de Roux N., Karges W. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J Endocrinol 2005, 186:377-385.
204. Arseven O.K., Wilkes W.P., Jameson J.L., Kopp P. Substitutions of tyrosine 601 in the human thyrotropin receptor result in increase or loss of basal activation of the cyclic adenosine monophosphate pathway and disrupt coupling to Gq/11. Thyroid 2000, 10:3-10.
205. Albertazzi E., Zanchetta D., Barbier P., et al. Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families. J Am Soc Nephrol 2000, 11:1033-1043.
206. Birnbaumer M., Gilbert S., Rosenthal W. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Mol Endocrinol 1994, 8:886-894.
207. Robben J.H., Knoers N.V., Deen P.M. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am J Physiol Renal Physiol 2005, 289:F265-F272.
208. Wildin R.S., Cogdell D.E., Valadez V. AVPR2 variants and V2 vasopressin receptor function in nephrogenic diabetes insipidus. Kidney Int 1998, 54:1909-1922.
209. Hermosilla R., Oueslati M., Donalies U., et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004, 5:993-1005.
210. Yokoyama K., Yamauchi A., Izumi M., et al. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 1996, 7:410-414.
211. Kopp P., van Sande J., Parma J., et al. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995, 332:150-154.
212. Winkler F., Kleinau G., Tarnow P., et al. A new phenotype of nongoitrous and nonautoimmune hyperthyroidism caused by a heterozygous thyrotropin receptor mutation in transmembrane helix 6. J Clin Endocrinol Metabolism 2010, 95:3605-3610.